Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib-Reference-Cited by-同舟云学术

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

Published:2024-09-13 Issue: Volume: Page:
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Pérez-Lamas Lucía,Díaz Adrián Segura,Casterá Elvira Mora,Soto Marta Hidalgo,Coll Antonio Paz,De las Heras Natalia,Cortes Montse,Tenza Patricia Vélez,Pacho Magdalena Sierra,Magan Alicia Senin,Angona Anna,Cervero Carlos,de Paz Raquel,Cuenca Araceli Salamanca,Santaliestra Marta,Marín Javier López,Casado Luis Felipe,García-Gutiérrez Valentín

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05906-6.pdf

Reference24 articles.

1. Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97(9):1236–1256. https://doi.org/10.1002/ajh.26642

2. Hochhaus A et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984. https://doi.org/10.1038/s41375-020-0776-2

3. Khoury HJ et al (2016) Cross-intolerance with Dasatinib among Imatinib-intolerant patients with chronic phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 16(6):341–349. https://doi.org/10.1016/j.clml.2016.03.004

4. Cortes JE et al (2011) Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117:5600–5606. https://doi.org/10.1182/blood-2010-11-318949

5. Cortes JE et al (2023) Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica 108(12):3454–3459. https://doi.org/10.3324/haematol.2022.281944